CSL (ASX:CSL) share price on watch after terminating COVID-19 vaccine trial

The CSL Limited (ASX:CSL) share price will be on watch today after it terminated trials of its COVID-19 vaccine…

| More on:
doctor holding covid-19 vaccine bottle

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price will be one to watch on Friday after the release of an update on its COVID-19 vaccine candidate.

What did CSL announce?

This morning CSL and the University of Queensland (UQ) announced results from the Phase 1 trial of the UQ-CSL v451 COVID-19 vaccine.

According to the release, the vaccine has shown that it elicits a robust response towards the virus and has a strong safety profile.

And while there were no serious adverse events or safety concerns reported, following agreement with the Australian Government, CSL will not progress the vaccine candidate to Phase 2/3 clinical trials.

Why is it not going any further?

The release explains that the Phase 1 data showed the generation of antibodies directed towards the "molecular clamp" component of the vaccine. These antibodies interfere with certain HIV diagnostic assays.

The potential for this cross-reaction had been anticipated prior to the commencement of the trial and participants were fully informed prior to their involvement.

Blood samples from participants were tested after vaccination and it was found that these molecular clamp antibodies did cause a false positive on a range of HIV assays.

Thankfully, follow up tests confirmed that there is no HIV virus present and that it was just a false positive on certain HIV tests. It stressed that there is no possibility the vaccine causes infection.

Nevertheless, following advice from experts, CSL and UQ have worked through the implications that this issue presents to rolling out the vaccine into broad populations and generally agreed that significant changes would need to be made to well-established HIV testing procedures in the healthcare setting to accommodate rollout of this vaccine.

Therefore, CSL and the Australian Government have agreed the vaccine development will not proceed to Phase 2/3 trials.

CSL's Chief Scientific Officer, Dr Andrew Nash, commented: "This outcome highlights the risk of failure associated with early vaccine development, and the rigorous assessment involved in making decisions as to what discoveries advance."

"This project has only been made possible by the innovative science developed by world-class scientists at The University of Queensland and the strong collaboration between our organisations, and many others, over the last 10 months. CSL and Seqirus are committed to continuing our work to protect the Australian population against COVID-19."

"Manufacture of approximately 30 million doses of the Oxford/AstraZeneca vaccine candidate is underway, with first doses planned for release to Australia early next year. In addition, CSL has agreed at the request of the Australian Government to manufacture an additional 20 million doses," he concluded.

CSL advised that it doesn't expect this development to have any impact on previously provided financial guidance for FY 2021.

Should you invest $1,000 in Bhp Group right now?

Before you buy Bhp Group shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Bhp Group wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors sent the market higher once again today.

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
Opinions

2 ASX shares I'd buy if the ASX crashes again

I think the best opportunities can be found when the market falls.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Share Market News

These ASX 200 stocks could rise 20% to 35%

These shares could be destined to deliver big returns over the next 12 months according to analysts.

Read more »

View of a mine site.
Broker Notes

How much upside does Macquarie tip for Deterra Royalties shares?

Deterra Royalties offers ASX investors a different way to invest in global mining.

Read more »

Rising gold share price represented by a green arrow on piles of gold block.
Gold

3 reasons to buy this surging ASX All Ords gold stock today

The ASX All Ords gold stock has doubled investors’ money in 12 months, and this leading expert forecasts more outperformance…

Read more »

Woman with $50 notes in her hand thinking, symbolising dividends.
Broker Notes

Broker reveals outlook for ASX dividend shares amid volatile market

Peter Gardner from Plato Investment Management tells ASX investors where to look for dividend income this year.

Read more »

Two colleagues at work looking at a tablet and smiling at a rising share price.
Share Gainers

Why Generation Development, Orica, Pro Medicus, and Zip shares are storming higher today

These shares are having a strong session on Thursday. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why ANZ, Brainchip, Light & Wonder, and Pilbara Minerals shares are falling today

These shares are tumbling on Thursday. But why?

Read more »